While BRAF V600E is typically associated with poor prognosis and increased tumor aggressiveness (13), evidence suggests that PD-1 blockade can partially overcome its negative prognostic impact in MSI-H/dMMR CRC (21). Here, BRAF is linked to colorectal carcinoma.